Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
123
Website
AMLX Metrics
BasicAdvanced
$726M
-
-$3.02
-0.59
-
Price and volume
Market cap
$726M
Beta
-0.59
52-week high
$8.72
52-week low
$2.60
Average daily volume
2M
Financial strength
Current ratio
12.807
Quick ratio
12.109
Long term debt to equity
0.162
Total debt to equity
0.686
Profitability
EBITDA (TTM)
-206.808
Gross margin (TTM)
7,790.41%
Net profit margin (TTM)
17,205.74%
Operating margin (TTM)
16,317.06%
Effective tax rate (TTM)
0.29%
Revenue per employee (TTM)
-$10,000
Management effectiveness
Return on assets (TTM)
-40.72%
Return on equity (TTM)
-83.24%
Valuation
Price to revenue (TTM)
-465.209
Price to book
3.6
Price to tangible book (TTM)
3.6
Price to free cash flow (TTM)
-2.432
Free cash flow yield (TTM)
-41.12%
Free cash flow per share (TTM)
-335.09%
Growth
Revenue change (TTM)
-100.32%
Earnings per share change (TTM)
185.96%
3-year revenue growth (CAGR)
64.64%
3-year earnings per share growth (CAGR)
-23.63%
Bulls say / Bears say
Amylyx Pharmaceuticals has initiated the Phase 3 LUCIDITY trial of avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy Designation, targeting post-bariatric hypoglycemia, with completion of recruitment expected in 2025 and topline data anticipated in the first half of 2026. (Amylyx Pharmaceuticals Press Release)
The company has commenced the Phase 1 LUMINA trial of AMX0114, an antisense oligonucleotide designed to target calpain-2 in ALS, with early cohort data expected in 2025. (Amylyx Pharmaceuticals Press Release)
Amylyx reported positive long-term results from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, demonstrating sustained stabilization or improvement in multiple outcomes related to disease progression at Week 48. (Amylyx Pharmaceuticals Press Release)
Amylyx voluntarily discontinued the marketing of RELYVRIO/ALBRIOZA for ALS after the Phase 3 PHOENIX trial failed to meet its primary endpoint, leading to a significant revenue loss. (Business Wire)
The company announced a restructuring plan that includes reducing its workforce by approximately 70% to focus resources on key clinical and preclinical programs, indicating financial and operational challenges. (Business Wire)
Amylyx's stock price has experienced significant volatility, with a recent decline to $6.30, reflecting investor concerns over the company's future prospects following the discontinuation of RELYVRIO/ALBRIOZA. (Amylyx Pharmaceuticals Press Release)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AMLX News
AllArticlesVideos
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Benzinga·2 weeks ago
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
Business Wire·2 weeks ago
Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $726M as of July 28, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of July 28, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.59. This means that it has an inverse relation to market volatility.